All batches independently tested by Janoshik
Research suggests that muscle lossas indicated by decreases in fat-free mass (which includes muscle as well as bones, water, and organs)with the medications ranges from 25% to 39% of total weight loss throughout 36 to 72 weeks, according to a 2024 study
VAT dropped by about 18% over 52 weeks vs placebo
Four of the 36 patients tested experienced mild adverse events such as blepharitis, keratitis, hyperemia, and ocular irritation, all of which resolved within 72 h
Retatrutide is currently investigational and is not FDA-approved for any indication
The complex is sensitive to reducing conditions that would convert copper(II) to copper(I) and to chelating agents that would displace the copper from the GHK ligand